Research
CeaseCancer
A Novel Disease-Modifying Therapy for Pancreatic Cancer
A Novel Disease-Modifying Therapy for Pancreatic Cancer, for effective and safe treatment where other therapies fail
CeaseCancer is developing a novel, disease-modifying biologic therapy for pancreatic cancer, one of the deadliest malignancies with ~10–12% 5-year survival and limited treatment options. Our approach is based on an optimized version of the human Klotho protein, engineered to enhance bioavailability, efficacy, and safety while selectively targeting cancer cells and sparing healthy tissue. Preclinical data demonstrate inhibition of tumor growth and strong synergy with chemotherapy, enabling lower, less toxic dosing. Unlike current therapies, CeaseCancer addresses core tumor biology and resistance mechanisms, offering potential as both monotherapy and combination treatment. With a clear development pathway toward clinical trials and strong market demand, CeaseCancer represents a differentiated opportunity to deliver transformative impact and significant value creation in oncology
CancerPredict
AI-Powered Biomarker Platform for Early Breast Cancer Risk Prediction
AI-Powered Biomarker Platform for Early Breast Cancer Risk Prediction
CancerPredict is an AI-powered biomarker platform designed to predict breast cancer years before it becomes detectable, addressing a critical gap in current risk assessment. Today’s models (e.g Tyrer/Cuzick) rely mainly on clinical questionnaires and fail to accurately identify which women will progress to cancer, leading to high false positives and missed high-risk patients.
CancerPredict combines multiplex immunohistochemistry (mIHC) with advanced machine learning to analyze biological signals directly from routine biopsy samples, generating a precise 5–10 year risk score. Seamlessly integrated into existing screening workflows, it requires no additional procedures while enabling earlier, personalized intervention.
Targeting a fast-growing global diagnostics market, CancerPredict offers a scalable kit-and-software business model with strong clinical and commercial potential, positioning it as a transformative solution in precision oncology and early cancer prevention
​
NES Pharma
Stopping Dementia Before It Starts
Developing the first preventive therapy for dementia by targeting glutamate-driven neurotoxicity at the MCI stage
NES Pharma is developing a first-in-class preventive therapy to stop dementia before it starts by targeting glutamate-driven neurotoxicity at the Mild Cognitive Impairment (MCI) stage—the last window for effective intervention. While current treatments offer limited benefit and focus on late-stage disease, NES Pharma addresses a core biological driver of neurodegeneration: glutamate dysregulation leading to neuronal damage and cognitive decline.
Our multimodal approach combines clinically validated mechanisms to reduce excess glutamate, protect neurons, and restore brain homeostasis through a safe, orally administered therapy suitable for long-term use. Positioned for broad application across neurodegenerative diseases, our solution aims to delay or prevent progression from MCI to dementia.
With a clear development roadmap toward clinical trials and strong partnering potential, NES Pharma targets a rapidly growing global market with significant unmet need, offering investors a differentiated, high-impact opportunity in neurodegenerative disease prevention.
​
AMP-Bio
Treatment for antibiotic resistant bacteria
Antibiotic resistant bacteria pose a serious threat to the global healthcare system.​
AMP-Bio develops antimicrobial-peptides (AMPs) for treating resistant bacteria, the treatment is anticipated to diminish the adverse effects on the microbiome of the patient.
Marathon
Longevity Treatment
Marathon develops a vehicle for safe administration in mitochondria replacement therapy (MRT).
Portfolio
Portfolio includes projects in various therapeutic fields and at different stages of development.